66 results on '"Abdool Karim, Quarraisha"'
Search Results
2. Identifying SARS-CoV-2 infections in South Africa: Balancing public health imperatives with saving lives.
- Author
-
Baxter, Cheryl, Abdool Karim, Quarraisha, and Abdool Karim, Salim S.
- Subjects
- *
SARS-CoV-2 , *CONTACT tracing , *TESTING laboratories , *PANDEMICS , *COVID-19 , *MEDICAL personnel , *PUBLIC health , *HEALTH facilities - Published
- 2021
- Full Text
- View/download PDF
3. Understanding women and men’s acceptability of current and new HIV prevention technologies in KwaZulu-Natal, South Africa.
- Author
-
Govender, Eliza and Abdool Karim, Quarraisha
- Subjects
- *
HIV prevention , *HIV infection risk factors , *HIV infection epidemiology , *AGE distribution , *CERVICAL caps , *HEALTH promotion , *SEXUAL health , *MEDICAL technology , *PREVENTIVE medicine , *PSYCHOLOGY of men , *METROPOLITAN areas , *NEGOTIATION , *NEW product development , *POPULATION geography , *RURAL conditions , *SEX distribution , *SPOUSES , *PSYCHOLOGY of women , *REPRODUCTIVE health , *ANTIRETROVIRAL agents , *THEMATIC analysis , *DISEASE prevalence - Abstract
Despite significant advances to the HIV epidemic, prevention remains a challenge globally. Adolescent girls and young women in southern and Eastern Africa are still at high risk of acquiring HIV infection with limited prevention options. The expanding product pipeline of novel drugs and delivery approaches has highlighted the importance of acceptability and uptake of these anti-retroviral based products to realize their full prevention potential. Community engagement is now imperative to inform both product development and uptake; with research directed to understand what potential users are willing to use given the broader cultural-gender context in which HIV prevention product choices are made/negotiated. We conducted ten gender specific discussion groups with 112 participants in three of the eight highest HIV prevalence districts in urban, peri-urban, and rural KwaZulu-Natal. The participants where purposively selected according to age, location and sex. The data was analysed thematically in terms of the key enablers and barriers of accepting three key HIV dosing strategies; the oral pill, the vaginal ring and the injectable among men and women. The study found that women are willing to consider HIV prevention options that align with their current sexual and reproductive health routines, offers the longest duration of protection, and requires minimal/no partner involvement, in contrast most men were not supportive of their partners using of any form of PrEP, irrespective of dosing strategies and formulations as it raised questions of infidelity and side effects on men. The findings is indicative of the complexities of women’s product choices, which are often embedded in a system of personal preference on an intrapersonal level, but also of male dominance, gender norms and cultural contexts at an interpersonal level. Understanding this intrapersonal-interpersonal interplay can enhance PrEP messaging and promotion; further highlighting the need to expand biomedical innovations for women initiated technologies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
4. Putting women in the centre of the global HIV response is key to achieving epidemic control!
- Author
-
Abdool Karim, Quarraisha, Havlir, Diane, and Phanuphak, Nittaya
- Subjects
- *
PRE-exposure prophylaxis , *VIOLENCE prevention , *HIV , *SYPHILIS , *HUMAN rights advocacy - Abstract
Keywords: women; HIV; prevention; treatment; transgender women; ageing EN women HIV prevention treatment transgender women ageing 1 3 3 04/01/20 20200301 NES 200301 As we celebrate International Women's Day and the many successes that women have, and continue to achieve globally, we are also reminded of the many challenges that remain. Sub-Saharan Africa bears a disproportionate 70% of the global burden of HIV that is spread predominantly through sex with a concomitant epidemic in infants born to mothers living with HIV. A unique characteristic of this generalized epidemic is the high rate of HIV in AGYW, who are up to six times more likely to have HIV compared to their male peers. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
5. Enhancing oral PrEP uptake among adolescent girls and young women in Africa.
- Author
-
Heck, Craig J. and Abdool Karim, Quarraisha
- Subjects
- *
YOUNG women , *TEENAGE girls , *HIV infections - Abstract
Therefore, for AGYW - whose HIV risk outweighs their risk of renal dysfunction - we propose immediate oral PrEP initiation, unless there is a history of renal dysfunction, as a safe and efficient approach for oral PrEP service delivery. In sub-Saharan Africa, adolescent girls and young women (AGYW, aged 15-24 years) bear a disproportionate burden of HIV infection, as they are more than twice as likely to acquire HIV than their male counterparts [1]. Fortunately, oral pre-exposure prophylaxis (PrEP) is a self-initiated option to reduce AGYW's HIV risk; however, oral PrEP uptake remains low among AYGW. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
6. Enhancing HIV Prevention with Injectable Preexposure Prophylaxis.
- Author
-
Karim, Quarraisha Abdool and Abdool Karim, Quarraisha
- Subjects
- *
HIV prevention , *PNEUMOCYSTIS pneumonia , *HIV infections , *ANTI-HIV agents , *PREVENTIVE health services , *AIDS - Published
- 2021
- Full Text
- View/download PDF
7. Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
- Author
-
Mansoor, Leila E., Abdool Karim, Quarraisha, Mngadi, Kathryn T., Dlamini, Sarah, Montague, Carl, Nkomonde, Nelisiwe, Mvandaba, Nomzamo, Baxter, Cheryl, Gengiah, Tanuja N., Samsunder, Natasha, Dawood, Halima, Grobler, Anneke, Frohlich, Janet A., and Abdool Karim, Salim S.
- Subjects
- *
FAMILY planning , *BIRTH control , *RANDOMIZED controlled trials , *CLINICAL trials monitoring - Abstract
Background The Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial demonstrated a 39% reduction in HIV infection, with a 54% HIV reduction in women who used tenofovir gel consistently. A confirmatory trial is expected to report results in early 2015. In the interim, we have a unique window of opportunity to prepare for and devise effective strategies for the future policy and programmatic scale-up of tenofovir gel provision. One approach is to integrate tenofovir gel provision into family planning (FP) services. The CAPRISA 008 implementation trial provides an opportunity to provide posttrial access to tenofovir gel while generating empiric evidence to assess whether integrating tenofovir gel provision into routine FP services can achieve similar levels of adherence as the CAPRISA 004 trial. Methods/design This is a two-arm, open-label, randomized controlled non-inferiority trial. A maximum of 700 sexually active, HIV-uninfected women aged 18 years and older who previously participated in an antiretroviral prevention study will be enrolled from an urban and rural site in KwaZulu-Natal, South Africa. The anticipated study duration is 30 months, with active accrual requiring approximately 12 months (following which an open cohort will be maintained) and follow-up continuing for approximately 18 months. At each of the two sites, eligible participants will be randomly assigned to receive tenofovir gel through either FP services (intervention arm) or through the CAPRISA research clinics (control arm). As part of the study intervention, a quality improvement approach will be used to assist the FP services to expand their current services to include tenofovir gel provision. Discussion This protocol aims to address an important implementation question on whether FP services are able to effectively incorporate tenofovir gel provision for this at-risk group of women in South Africa. Provision of tenofovir gel to the women from the CAPRISA 004 trial meets the ethical obligation for post-trial access, and helps identify a potential avenue for future scaleup of microbicides within the public health system of South Africa. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
8. Low adverse event rates following voluntary medical male circumcision in a high HIV disease burden public sector prevention programme in South Africa.
- Author
-
Phili, Rogerio, Abdool‐Karim, Quarraisha, and Ngesa, Oscar
- Abstract
Introduction: The provision of voluntary medical male circumcision (VMMC) services was piloted in three public sector facilities in a high HIV disease burden, low circumcision rate province in South Africa to inform policy and operational guidance for scaleup of the service for HIV prevention. We report on adverse events (AEs) experienced by clients following the circumcision procedure. Methods: Prospective recruitment of HIV-negative males aged 12 and older volunteering to be circumcised at three select public health facilities in KwaZulu-Natal between November 2010 and May 2011. Volunteers underwent standardized medical screening including a physical assessment prior to the surgical procedure being performed. AEs were monitored at three time intervals over a 21-day period post-operatively to determine safety outcomes in this pilot demonstration programme. Results: A total of 602 volunteers participated in this study. The median age of the volunteers was 22 years (range 12-56). Most participants (75.6%) returned for the 48-hour post-operative visit; 51.0% for day seven visit and 26.1% for the 21st day visit. Participants aged 20-24 were most likely to return. The AE rate was 0.2% intra-operatively. The frequency of moderate AEs was 0.7, 0.3 and 0.6% at 2-, 7- and 21-day visits, respectively. The frequency of severe AEs was 0.4, 0.3 and 0.6% at 2-, 7- and 21-day visits, respectively. Swelling and wound infection were the most common AEs with mean appearance duration of seven days. Clients aged between 35 and 56 years presented with most AEs (3.0%). Conclusions: VMMC can be delivered safely at resource-limited settings. The intensive three-visit post-operative review practice may be unfeasible due to high attrition rates over time, particularly amongst older men. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. HIV recency testing: should results be disclosed to individuals tested?
- Author
-
Abdool Karim, Quarraisha, Macklin, Ruth, Gruskin, Sofia, Klucking, Sara, Lockett, Lejeune, Maxwell, Celia J, Mayer, Kenneth H, Sanders, Edwin, and Sawe, Frederick
- Subjects
- *
HIV infections , *HIV seroconversion , *PUBLIC health surveillance , *HIV infection transmission - Published
- 2020
- Full Text
- View/download PDF
10. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women.
- Author
-
Abdool Karim, Quarraisha, Abdool Karim, Salim S., Frohlich, Janet A., Grobler, Anneke C., Baxter, Cheryl, Mansoor, Leila E., Kharsany, Ayesha B. M., Sibeko, Sengeziwe, Mlisana, Koleka P., Omar, Zaheen, Gengiah, Tanuja N., Maarschalk, Silvia, Arulappan, Natasha, Mlotshwa, Mukelisiwe, Morris, Lynn, and Taylor, Douglas
- Subjects
- *
CLINICAL drug trials , *ANTIRETROVIRAL agents , *HIV prevention , *RESEARCH methodology , *BLIND experiment , *RANDOMIZED controlled trials , *PLACEBOS , *AIDS in women - Abstract
The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase inhibitor, for the prevention of HIV acquisition in women. A double-blind, randomized controlled trial was conducted comparing tenofovir gel (n = 445 women) with placebo gel (n = 444 women) in sexually active, HIV-uninfected 18- to 40-year-old women in urban and rural KwaZulu-Natal, South Africa. HIV serostatus, safety, sexual behavior, and gel and condom use were assessed at monthly follow-up visits for 30 months. HIV incidence in the tenofovir gel arm was 5.6 per 100 women-years (person time of study observation) (38 out of 680.6 women-years) compared with 9.1 per 100 women-years (60 out of 660.7 women-years) in the placebo gel arm (incidence rate ratio = 0.61; P = 0.017). In high adherers (gel adherence > 80%), HIV incidence was 54% lower (P = 0.025) in the tenofovir gel arm. In intermediate adherers (gel adherence 50 to 80%) and low adherers (gel adherence < 50%), the HIV incidence reduction was 38 and 28%, respectively. Tenofovir gel reduced HIV acquisition by an estimated 39% overall, and by 54% in women with high gel adherence. No increase in the overall adverse event rates was observed. There were no changes in viral load and no tenofovir resistance in HIV seroconverters. Tenofovir gel could potentially fill an important HIV prevention gap, especially for women unable to successfully negotiate mutual monogamy or condom use. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
11. HIV prevention for the next decade: Appropriate, person-centred, prioritised, effective, combination prevention.
- Author
-
Godfrey-Faussett, Peter, Frescura, Luisa, Abdool-Karim, Quarraisha, Clayton, Michaela, Ghys, Peter D., and (on behalf of the 2025 prevention targets working group)
- Abstract
UNAIDS and a broad range of partners have collaborated to establish a new set of HIV prevention targets to be achieved by 2025 as an intermediate step towards the sustainable development target for 2030.The number of new HIV infections in the world continues to decline, in part due to the extraordinary expansion of effective HIV treatment. However, the decline is geographically heterogeneous, with some regions reporting a rise in incidence. The incidence target that was agreed for 2020 has been missed.A range of exciting new HIV prevention technologies have become available or are in the pipeline but will only have an impact if they are accessible and affordable and delivered within systems that take full account of the social and political context in which most infections occur. Most new infections occur in populations that are marginalised or discriminated against due to structural, legal, and cultural barriers.The new targets imply a new approach to HIV prevention that emphasises appropriate, person-centred, prioritised, effective, combination HIV prevention within a framework that reduces existing barriers to services and acknowledges heterogeneity, autonomy, and choice.These targets have consequences for people working in HIV programmes both for delivery and for monitoring and evaluation, for health planners setting local and national priorities, and for funders both domestic and global. Most importantly, they have consequences for people who are at risk of HIV exposure and infection.Achieving these targets will have a huge impact on the future of the HIV epidemic and put us back on track towards ending AIDS as a public health threat by 2030. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Sexually transmitted infections in pregnancy and adverse pregnancy outcomes: A retrospective cohort study.
- Author
-
Govender, Vani, Moodley, Dhayendre, Naidoo, Megeshinee, Connoly, Cathy, Ngcapu, Sinaye, and Abdool Karim, Quarraisha
- Subjects
- *
PREGNANCY outcomes , *SEXUALLY transmitted diseases , *TEENAGE pregnancy , *LOW birth weight , *TRICHOMONAS vaginalis - Abstract
Objective: There is a high prevalence and incidence rate of asymptomatic sexually transmitted infections (STIs) during pregnancy in adolescent girls and young women in Africa. The association between STIs and pregnancy outcomes in a hyperepidemic HIV setting has not been well described. Methods: Pregnant women, HIV‐1 negative and <28 weeks' gestation at three primary health clinics in KwaZulu‐Natal, South Africa were enrolled from February 2017 to March 2018. Vaginal swabs collected at the first and later antenatal visits were stored and retrospectively tested for HSV‐2, Trichomonas vaginalis, Chlamydia trachomatis and Neisseria gonorrhoeae at the end of the study. The association between STIs detected at first and later antenatal visits and pregnancy outcome was assessed using multivariable logistic regression models adjusted for maternal age and treatment received for symptomatic STIs. Results: Testing positive Mycoplasma genitalium at the first antenatal visit was significantly associated with low birth weight (odds ratio [OR] 5.22; 95% confidence interval [CI]: 1.10–15.98). Testing positive for T. vaginalis at the repeat visit was significantly associated with preterm births (OR 2.37; 95% CI: 1.11–5.03), low birth weight (OR 2.56; 1.16–5.63) and a composite adverse pregnancy outcome (OR 2.11; 95% CI: 1.09–4.08). Testing positive for HSV‐2 at the repeat visit was also likely associated with experiencing a preterm birth or any adverse pregnancy outcome (OR 3.39; 95% CI: 0.86–13.3) (P = 0.096). Conclusions: Among predominantly asymptomatic STIs, M. genitalium detected at baseline visit was significantly associated with low birth weight, while T. vaginalis detected at the repeat visit in later pregnancy was significantly associated with preterm birth. Further research is warranted to study the impact of etiological testing of STIs at more than one antenatal visit and empirical treatment on pregnancy outcomes. Synopsis: In a retrospective cohort study, etiological testing revealed a strong association between Mycoplasma genitalium and Trichomonas vaginalis with low birth weight and preterm birth, respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Informed Consent for HIV Testing in a South African Hospital: Is It Truly Informed and Truly Voluntary?
- Author
-
Abdool Karim, Quarraisha, Abdool Karim, Salim S., Coovadia, Hoosen M., and Susser, Mervyn
- Subjects
- *
HIV , *INFORMED consent (Medical law) , *MEDICAL screening , *HIV infection transmission , *MEDICAL ethics - Abstract
Objective. The purpose of this study was to assess informed consent to human immunodeficiency virus (HIV) testing in a perinatal HIV transmission study in a major referral hospital serving a largely Black population in South Africa. Methods. First-time antenatal clinic attenders who were randomly selected from those enrolled in the perinatal HIV study (n = 56) answered questionnaires before and after counseling. Results. Knowledge of HIV transmission and prevention, high at the outset, was little improved after counseling. The acceptance rate for HIV testing was high. Despite assurances that participation was voluntary, 88% of the women said they felt compelled to participate in the study. Conclusions. Informed consent in this setting was truly informed but not truly voluntary. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
14. Tenofovir Gel to Prevent HSV-2 Infection.
- Author
-
Abdool Karim, Salim S., Abdool Karim, Quarraisha, and Gengiah, Tanuja N.
- Subjects
- *
TENOFOVIR , *HERPES genitalis , *HERPES simplex virus - Abstract
A response from the authors of a study about the use of tenofovir gel in treating genital herpes simplex virus type 2 (HSV-2) infection is presented.
- Published
- 2015
- Full Text
- View/download PDF
15. HIV—No time for complacency.
- Author
-
Abdool Karim, Quarraisha and Abdool Karim, Salim S.
- Subjects
- *
HIV infections , *THERAPEUTICS , *HIV infection risk factors , *HIV-positive persons , *ATTITUDES toward AIDS (Disease) , *SOCIAL stigma , *ANTIRETROVIRAL agents - Abstract
An editorial is presented on the decline in efforts to eliminate HIV. It states that nearly 30 new antiretroviral drugs that are inexpensive, have minimal side effects, and only need be taken once a day have allowed HIV-positive people to live a nearly normal life span. It mentions that despite beliefs the AIDS epidemic is over, nearly 5,000 new cases of HIV infection occur daily and talks about the stigma that HIV-positive people have to live with.
- Published
- 2018
- Full Text
- View/download PDF
16. Identification of adolescent girls and young women for targeted HIV prevention: a new risk scoring tool in KwaZulu Natal, South Africa.
- Author
-
Ayton, Sarah Gabrielle, Pavlicova, Martina, and Abdool Karim, Quarraisha
- Subjects
- *
HIV , *TEENAGE girls , *YOUNG women , *PREVENTIVE medicine - Abstract
The ongoing spread of human immunodeficiency virus (HIV) has driven novel interventions, such as antiretrovirals, for pre-exposure prophylaxis. Interventions have overlooked a high-risk Sub-Saharan African population: adolescent girls and young women (AGYW), particularly those under 18. We apply the Balkus risk tool among rural South African AGYW (n = 971) in a hyper-endemic setting, identify limitations, and assess deficiencies with modern statistical techniques. We apply the "Ayton" tool, the first risk tool applicable to sub-Saharan African AGYW, and compare performance of Balkus and Ayton tools under varying conditions. The Ayton tool more effectively predicted HIV acquisition. In low and high-risk AGYW, the Ayton tool out-performed the Balkus tool, which did not distinguish between risk classes. The Ayton tool better captured HIV acquisition risk and risk heterogeneities due to its AGYW-focused design. Findings support use of the Ayton tool for AGYW and underscore the need for diverse prognostic tools considering epidemic severity, age, sex and transmission. Clinical Trial Number ClinicalTrials.gov (NCT01187979) and the South African National Clinical Trials Registry (SANCTR) (DOH-27-0812-3345). [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Anti-retrovirals for treatment and prevention - time for new paradigms in our response to the HIV/AIDS epidemic?
- Author
-
Abdool Karim, Quarraisha and Bayer, Ronald
- Subjects
- *
ANTIRETROVIRAL agents , *HIV prevention , *TENOFOVIR , *EMTRICITABINE , *DRUG approval , *DRUG labeling - Abstract
The author reflects on the effectivity of antiretroviral drugs as treatment for human immunodeficiency virus (HIV). The author says that the U.S. Food and Drug Administration (FDA) has approved the relabeling of tenofovir and emtricitabine as prophylactic agents. He states that antiretrovirals reduces the possibility of viral transmission and lessen viral load to HIV positive individuals. Moreover, antiretroviral agents also provides protection to uninfected individual.
- Published
- 2013
- Full Text
- View/download PDF
18. HIV and maternal mortality: turning the tide.
- Author
-
Abdool-Karim, Quarraisha, AbouZahr, Carla, Dehne, Karl, Mangiaterra, Viviana, Moodley, Jack, Rollins, Nigel, Say, Lale, Schaffer, Nathan, Rosen, James E., and De Zoysa, Isabelle
- Subjects
- *
HIV-positive women , *MATERNAL mortality , *PREGNANCY complications , *CHILDBIRTH , *WOMEN'S mortality , *PREGNANT women - Abstract
The authors reflect on various issues concerning HIV and maternal mortality. They reveal that the top causes of death among women who are of reproductive age are HIV/AIDS and pregnancy- and childbirth-related complications. They explain the increased risk of death among pregnant women diagnosed with HIV and emphasize the importance of understanding the dimensions and pathways of mortality risk. They also argue that reducing mortality among HIV-infected women requires collaboration and improvements in antenatal and obstetric care.
- Published
- 2010
- Full Text
- View/download PDF
19. Vertical HIV transmission in South Africa: translating research into policy and practice.
- Author
-
Abdool Karim, Salim, Abdool Karim, Quarraisha, Adhikari, Miriam, Cassol, Sharon, Chersich, Matthew, Cooper, Peter, Coovadia, Ashraf, Coovadia, Hoosen, Cotton, Mark, Coutsoudis, Anna, Hide, Win, Hussey, Greg, Maartens, Gary, Madhi, Shabir, Martin, Des, Pettifor, John M, Rollins, Nigel, Sherman, Gayle, Thula, Stanley, and Urban, Michael
- Subjects
- *
HIV , *BREASTFEEDING , *INFECTIOUS disease transmission , *DRUGS , *HEALTH - Abstract
Discusses the rate of vertical transmission of HIV (from mothers to children) in South Africa. Effects of breast-feeding on the transmission; Effects of antiretroviral drugs on the spread of the disease; Idea that half of vertical transmission cases could be prevented by short-course antiretroviral drug regimens; Issue of drug-resistance.
- Published
- 2002
- Full Text
- View/download PDF
20. Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
- Author
-
Mansoor, Leila E, Abdool Karim, Quarraisha, Mngadi, Kathryn T, Dlamini, Sarah, Montague, Carl, Nkomonde, Nelisiwe, Mvandaba, Nomzamo, Baxter, Cheryl, Gengiah, Tanuja N, Samsunder, Natasha, Dawood, Halima, Grobler, Anneke, Frohlich, Janet A, and Abdool Karim, Salim S
- Abstract
Background: The Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial demonstrated a 39% reduction in HIV infection, with a 54% HIV reduction in women who used tenofovir gel consistently. A confirmatory trial is expected to report results in early 2015. In the interim, we have a unique window of opportunity to prepare for and devise effective strategies for the future policy and programmatic scale-up of tenofovir gel provision. One approach is to integrate tenofovir gel provision into family planning (FP) services. The CAPRISA 008 implementation trial provides an opportunity to provide post-trial access to tenofovir gel while generating empiric evidence to assess whether integrating tenofovir gel provision into routine FP services can achieve similar levels of adherence as the CAPRISA 004 trial.Methods/design: This is a two-arm, open-label, randomized controlled non-inferiority trial. A maximum of 700 sexually active, HIV-uninfected women aged 18 years and older who previously participated in an antiretroviral prevention study will be enrolled from an urban and rural site in KwaZulu-Natal, South Africa. The anticipated study duration is 30 months, with active accrual requiring approximately 12 months (following which an open cohort will be maintained) and follow-up continuing for approximately 18 months. At each of the two sites, eligible participants will be randomly assigned to receive tenofovir gel through either FP services (intervention arm) or through the CAPRISA research clinics (control arm). As part of the study intervention, a quality improvement approach will be used to assist the FP services to expand their current services to include tenofovir gel provision.Discussion: This protocol aims to address an important implementation question on whether FP services are able to effectively incorporate tenofovir gel provision for this at-risk group of women in South Africa. Provision of tenofovir gel to the women from the CAPRISA 004 trial meets the ethical obligation for post-trial access, and helps identify a potential avenue for future scale-up of microbicides within the public health system of South Africa.Trial Registration: This trial was registered with the South Africa Department of Health (reference: DOH-27-0812-4129) and ClinicalTrials.gov (reference: NCT01691768) on 05 July 2012. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
21. Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.
- Author
-
Govender, Eliza M., Mansoor, Leila E., and Abdool Karim, Quarraisha
- Subjects
- *
HIV prevention , *ANTI-HIV agents , *ACTION research , *CONFIDENCE , *DRUG utilization , *PHARMACEUTICAL gels , *HEALTH attitudes , *SEXUAL health , *PREVENTIVE medicine , *METROPOLITAN areas , *RURAL conditions , *RURAL health , *SOCIAL classes , *URBAN health , *WOMEN'S health , *PATIENT participation , *THEMATIC analysis , *TENOFOVIR - Abstract
Young women bear a disproportionately high burden of HIV infection in sub-Saharan Africa, prioritising pre-exposure prophylaxis (PrEP) can be an integral part of HIV prevention combination strategies. Women initiated HIV prevention technology options will require consistent adherence, an imperative for product effectiveness. With several PrEP clinical trials underway; exploring women’s acceptability to advances in HIV prevention technologies can better facilitate demand creation for future PrEP roll out. This study utilised the opportunity of post-trial access to CAPRISA 008 women (trial) and non-trial women from three geo-spatial settings (urban, rural and peri-urban) to identify microbicide acceptability and how product associations of microbicides can influence future HIV prevention choices. Six participatory workshops using participatory action research with art-based activities and discussion groups were conducted in KwaZulu-Natal with 104 women from various geo-spatial locations and social status to understand microbicide acceptability and product associations. The data were analysed using thematic analysis. The study found that women’s acceptability and product association of the tenofovir gel microbicide differed according to rural and urban areas. Most urban women identified confidence, sexiness and classiness as key associations that will encourage microbicide acceptability and use, while rural women identified respect, responsibility and confidence as the key product associations, with increased focus on the individual and collective family/community benefits of product acceptance and use. Urban–rural differences suggest a market segmentation that is contextualised to be locally responsive to promote HIV prevention technologies. Various sexual encounters further determined the types of HIV prevention technologies women would consider. In line with WHO’s recommendation that PrEP should be an additional prevention choice for people at risk of HIV, this study underscores the importance of user engagement, understanding product associations and how this can influence product acceptability and promotion of HIV prevention technologies. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
22. Diverse approaches useful for microbicide trials.
- Author
-
Abdool Karim, Salim S. and Abdool Karim, Quarraisha
- Subjects
- *
LETTERS to the editor , *HIV - Abstract
A letter to the editor is presented in response to the article "HIV trial doomed by design" in the 2007 issue.
- Published
- 2007
- Full Text
- View/download PDF
23. HIV treatment in South Africa: overcoming impediments to get started.
- Author
-
Abdool Karim, Quarraisha
- Subjects
- *
APARTHEID , *AIDS , *HIV , *ANTIRETROVIRAL agents , *PUBLIC health - Abstract
Discusses the effect that HIV/AIDS has had on the peaceful transition from apartheid in South Africa. Milestones in access to treatment for HIV in South Africa; Details of highly active antiretroviral therapy; Percentage of pregnent women who have HIV; Opposition by advocacy groups against the government decision not to provide-two dose nevirapine treatment to reduce the risk of mother-to-child transmission of HIV; Adoption of the national treatment plan by the government after they recognized that about half a million South Africans were in need of antiretroviral treatment. INSET: Milestones in access to treatment for HIV in South Africa.
- Published
- 2004
- Full Text
- View/download PDF
24. Antiretroviral therapy: challenges and options in South Africa.
- Author
-
Abdool Karim, Salim S., Abdool Karim, Quarraisha, and Baxter, Cheryl
- Subjects
- *
LETTERS to the editor , *HEALTH policy - Abstract
Presents a letter to the editor about the August 16 Editorial on the decision of South Africa to give the public sector access to antiretroviral therapy in response to the HIV-1/AIDS epidemic.
- Published
- 2003
- Full Text
- View/download PDF
25. Vaginal microbial shifts are unaffected by oral pre-exposure prophylaxis in South African women.
- Author
-
Mazibuko-Motau, Noluthando, Sobia, Parveen, Xu, Jiawu, Elsherbini, Joseph Ahmed, San, James E., Lewis, Lara, Mtshali, Andile, Mzobe, Gugulethu, Ntuli, Lungelo, Abdool Karim, Salim S., Mansoor, Leila E., Abdool Karim, Quarraisha, Kwon, Douglas S., Archary, Derseree, and Ngcapu, Sinaye
- Abstract
Vaginal microbiota have been shown to be a modifier of protection offered by topical tenofovir in preventing HIV infection in women, an effect not observed with oral tenofovir-based pre-exposure prophylaxis (PrEP). It remains unclear whether PrEP can influence the vaginal microbiota composition. This study investigated the impact of daily oral tenofovir disoproxil fumarate in combination with emtricitabine for PrEP on the vaginal microbiota in South African women. At baseline, Lactobacillus iners or Gardnerella vaginalis dominant vaginal communities were observed in the majority of participants. In cross sectional analysis, vaginal microbiota were not affected by the initiation and use of PrEP. Longitudinal analysis revealed that Lactobacillus crispatus-dominant "cervicotypes 1 (CT1)" communities had high probability of remaining stable in PrEP group, but had a higher probability of transitioning to L. iners-dominant CT2 communities in non-PrEP group. L. iners-dominant communities were more likely to transition to communities associated with bacterial vaginosis (BV), irrespective of PrEP or antibiotic use. As expected, BV-linked CTs had a higher probability of transitioning to L. iners than L. crispatus dominant CTs and this shift was not associated with PrEP use. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Exploring discrepant knowledge of partner sexual behaviour to inform self-risk assessment in a high HIV burdened district in rural KwaZulu-Natal.
- Author
-
Humphries, Hilton, Knight, Lucia, Mehou-Loko, Celia, Mdladla, Makhosazana, Phakathi, Sthembile, Mazibuko, Sindisiwe, and Abdool Karim, Quarraisha
- Subjects
- *
HIV infection epidemiology , *RISK-taking behavior , *HUMAN sexuality , *RURAL conditions , *RESEARCH methodology , *AGE distribution , *INTERVIEWING , *RISK assessment , *HEALTH literacy , *SEX customs , *QUESTIONNAIRES , *DESCRIPTIVE statistics , *RESEARCH funding , *SEXUAL partners , *JUDGMENT sampling , *DATA analysis software , *THEMATIC analysis - Abstract
Understanding the sexual relationships of young women is critical for preventing HIV infections. This study aimed to describe the sexual behaviour of partners, comparing the accuracy of sexual health knowledge between partners. The study took place in 2017 in KwaZulu-Natal, South Africa. Purposive sampling was used to select 18–27-year-old sexually active women. Consenting female participants completed a structured and semi-structured interview, while consenting male sexual partners identified through the female participant completed a structured questionnaire on sexual health information. Using a reflexive inductive approach and thematic analysis, we identified key discrepancies in the assumptions partners make about each other's sexual health information. Twenty-three sexual dyads were identified and four key discrepancies were identified: Age: partners either over or underestimated the age of their partners, HIV status: where partners were unaware of, or incorrectly assumed their partner's status, Lack of awareness of partner's concurrent relationships and more general knowledge of the partner's sexual health behaviours. Discussions about sexual health are mediated by relationship length, type of partner, power and perceived fidelity. While it is possible to undertake dyadic level research, ethical tensions remain. Sex-positive and egalitarian sexual health interventions that target the individual, as well as the sexual relationship, are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Prospective study of oral pre‐exposure prophylaxis initiation and adherence among young women in KwaZulu‐Natal, South Africa.
- Author
-
Mansoor, Leila E., Lewis, Lara, Naicker, Cherise L., Harkoo, Ishana, Dawood, Halima, Naidoo, Kalendri, Gengiah, Tanuja N., Samsunder, Natasha, Beesham, Ivana, Abdool Karim, Salim S., and Abdool Karim, Quarraisha
- Subjects
- *
PRE-exposure prophylaxis , *YOUNG women , *HIV prevention , *LONGITUDINAL method , *POISSON regression - Abstract
Introduction: Oral tenofovir disoproxil fumarate/emtricitabine pre‐exposure prophylaxis (PrEP), introduced into South Africa (SA) in 2016, has increasingly become part of HIV prevention standard of care. Given the urgent need for increased HIV prevention efforts for young women in SA, we conducted an implementation study to explore oral PrEP initiation and adherence, and the impact of oral PrEP on HIV incidence in this group. Methods: This prospective cohort study (CAPRISA 082) was conducted at two sites (urban and rural) in KwaZulu‐Natal, between March 2016 and February 2018. HIV‐negative, sexually active women, aged 18–30 years, were enrolled and followed for approximately 10 months. Oral PrEP was offered as part of a comprehensive HIV prevention package. Adherence to oral PrEP was measured using pill counts and tenofovir‐diphosphate (TFV‐DP) levels. Characteristics of oral PrEP initiators versus non‐initiators were compared using risk ratios. HIV incidence rates were measured using Poisson regression. Results: Of 425 women enrolled, 262 (62%) initiated oral PrEP. Uptake was significantly higher at the rural site compared to the urban site (78% [n = 203/259] vs. 36% [n = 59/166], respectively, p‐value<0.001). Approximately 25% and 50% had stopped using oral PrEP by 3 and 12 months post‐initiation, respectively. Median pill count adherence was 90% (interquartile range: 81–97%); however, TFV‐DP was only detected in 13% of samples tested, that is 56/431 samples from 97 (37%) participants who initiated oral PrEP. In total, 11 women seroconverted yielding an HIV incidence rate of 2.81 per 100 person‐years (95% confidence interval: 1.40–5.03). Nine of 11 seroconverters had initiated oral PrEP; however, all showed drug levels equivalent to taking one to zero tablets per week. Among women who initiated oral PrEP, >50% had discontinued using oral PrEP by study end, with side effects, such as diarrhoea, nausea, headaches and rash, being the most frequent reason for discontinuation. Conclusions: Despite moderate oral PrEP initiation and high pill count adherence, adherence as measured by TFV‐DP levels was low and early discontinuation was high. The overall HIV incidence rate was high underscoring the critical need to address barriers to oral PrEP initiation, adherence and continued use, as well as expanding HIV prevention options for young women. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. ARV-based HIV prevention for women - where we are in 2014.
- Author
-
Mastro, Timothy D, Sista, Nirupama, and Abdool-Karim, Quarraisha
- Subjects
- *
HIV prevention , *DISEASES in women , *ANTIRETROVIRAL agents , *PRE-exposure prophylaxis , *HIV infections - Abstract
Women continue to be at special risk for HIV acquisition due to a complex mix of biological, behavioural, structural, cultural and social factors, with unacceptable rates of new infection. Scientific advances over the past decade have highlighted the use of antiretroviral (ARV) drugs as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition (sexually, parenterally and vertically) and ARV treatment (ART) for HIV-positive patients to prevent onward transmission (treatment as prevention - TasP). This paper reviews the evidence base for PrEP and TasP, describes new products in development and the need to translate research findings into programmes with impact at the population level. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
29. ARV-based HIV prevention for women - where we are in 2014.
- Author
-
Mastro, Timothy D., Sista, Nirupama, and Abdool-Karim, Quarraisha
- Subjects
- *
HIV prevention , *ANTIRETROVIRAL agents , *WOMEN'S health , *SOCIAL factors , *SOCIOCULTURAL factors , *SEXUALLY transmitted diseases - Abstract
Women continue to be at special risk for HIV acquisition due to a complex mix of biological, behavioural, structural, cultural and social factors, with unacceptable rates of new infection. Scientific advances over the past decade have highlighted the use of antiretroviral (ARV) drugs as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition (sexually, parenterally and vertically) and ARV treatment (ART) for HIV-positive patients to prevent onward transmission (treatment as prevention - TasP). This paper reviews the evidence base for PrEP and TasP, describes new products in development and the need to translate research findings into programmes with impact at the population level. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
30. Pre-infection plasma cytokines and chemokines as predictors of HIV disease progression.
- Author
-
Ngcobo, Samukelisiwe, Molatlhegi, Refilwe P., Osman, Farzana, Ngcapu, Sinaye, Samsunder, Natasha, Garrett, Nigel J., Abdool Karim, Salim S., Abdool Karim, Quarraisha, McKinnon, Lyle R., and Sivro, Aida
- Subjects
- *
DISEASE progression , *CHEMOKINES , *HIV infections , *SOUTH Africans , *VIRAL load , *CYTOKINES , *PEAK load - Abstract
Previous studies have highlighted the role of pre-infection systemic inflammation on HIV acquisition risk, but the extent to which it predicts disease progression outcomes is less studied. Here we examined the relationship between pre-infection plasma cytokine expression and the rate of HIV disease progression in South African women who seroconverted during the CAPRISA 004 tenofovir gel trial. Bio-Plex 200 system was used to measure the expression of 47 cytokines/chemokines in 69 seroconvertors from the CAPRISA 004 trial. Cox proportional hazards regression analyses were used to measure associations between cytokine expression and CD4 decline prior to antiretroviral therapy initiation. Linear regression models were used to assess whether pre-infection cytokine expression were predictors of disease progression outcomes including peak and set-point viral load and CD4:CD8 ratio at less and greater than180 days post infection. Several cytokines were associated with increased peak HIV viral load (including IL-16, SCGFβ, MCP-3, IL-12p40, SCF, IFNα2 and IL-2). The strongest association with peak viral load was observed for SCGFβ, which was also inversely associated with lowest CD4:CD8 ratio < 180 days post infection and faster CD4 decline below 500 cells/µl (adjusted HR 4.537, 95% CI 1.475–13.954; p = 0.008) in multivariable analysis adjusting for age, study site, contraception, baseline HSV-2 status and trial arm allocation. Our results show that pre-infection systemic immune responses could play a role in HIV disease progression, especially in the early stages of infection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. Implants for HIV prevention in young women: Provider perceptions and lessons learned from contraceptive implant provision.
- Author
-
Humphries, Hilton, Upfold, Michele, Mahlase, Gethwana, Mdladla, Makhosazana, Gengiah, Tanuja N., and Abdool Karim, Quarraisha
- Subjects
- *
HIV prevention , *CONTRACEPTION , *MEDICAL personnel , *CONTRACEPTIVES , *HIV infections , *DRUG delivery devices , *YOUNG women , *HIV - Abstract
Preventing new HIV infections, especially amongst young women, is key to ending the HIV epidemic especially in sub-Saharan Africa. Potent antiretroviral (ARV) drugs used as pre-exposure prophylaxis (PrEP) are currently being formulated as long-acting implantable devices, or nanosuspension injectables that release drug at a sustained rate providing protection from acquiring HIV. PrEP as implants (PrEP Implants) offers an innovative and novel approach, expanding the HIV prevention toolbox. Feedback from providers and future users in the early clinical product development stages may identify modifiable characteristics which can improve acceptability and uptake of new technologies. Healthcare workers (HCWs) perspectives and lessons learned during the rollout of contraceptive implants will allow us to understand what factors may impact the roll-out of PrEP implants. We conducted eighteen interviews with HCWs (9 Nurses and 9 Community Healthcare Workers) in rural KwaZulu-Natal, South Africa. HCWs listed the long-acting nature of the contraceptive implant as a key benefit, helping to overcome healthcare system barriers like heavy workloads and understaffing. However, challenges like side effects, migration of the implant, stakeholder buy-in and inconsistent training on insertion and removal hampered the roll-out of the contraceptive implant. For PrEP implants, HCWs preferred long-acting products that were palpable and biodegradable. Our findings highlighted that the characteristics of PrEP implants that are perceived to be beneficial by HCWs may not align with that of potential users, potentially impacting the acceptability and uptake of PrEP implants. Further our data highlight the need for sustained and multi-pronged approaches to training HCWs and introducing new health technologies into communities. Finding a balance between the needs of HCWs that accommodate their heavy workloads, limited resources at points of delivery of care and the needs and preferences of potential users need to be carefully considered in the development of PrEP implants. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
32. Higher mucosal antibody concentrations in women with genital tract inflammation.
- Author
-
Sobia, Parveen, Pillay, Thevani, Liebenberg, Lenine J. P., Sivro, Aida, Mansoor, Leila E., Osman, Farzana, Passmore, Jo-Ann S., Abdool Karim, Quarraisha, Abdool Karim, Salim S., Baxter, Cheryl, McKinnon, Lyle R., and Archary, Derseree
- Subjects
- *
IMMUNOGLOBULIN M , *GENITALIA , *IMMUNOGLOBULINS , *IMMUNOGLOBULIN G , *ANTIBODY formation , *HIV infections , *GROWTH factors - Abstract
Inflammatory cytokines augment humoral responses by stimulating antibody production and inducing class-switching. In women, genital inflammation (GI) significantly modifies HIV risk. However, the impact of GI on mucosal antibodies remains undefined. We investigated the impact of GI, pre-HIV infection, on antibody isotypes and IgG subclasses in the female genital tract. Immunoglobulin (Ig) isotypes, IgG subclasses and 48 cytokines were measured prior to HIV infection in cervicovaginal lavages (CVL) from 66 HIV seroconverters (cases) and 66 matched HIV-uninfected women (controls) enrolled in the CAPRISA 004 and 008 1% tenofovir gel trials. Pre-HIV infection, cases had significantly higher genital IgM (4.13; IQR, 4.04–4.19) compared to controls (4.06; IQR, 3.90–4.20; p = 0.042). More than one-quarter of cases (27%) had GI compared to just over one-tenth (12%) in controls. Significantly higher IgG1, IgG3, IgG4 and IgM (all p < 0.05) were found in women stratified for GI compared to women without. Adjusted linear mixed models showed several pro-inflammatory, chemotactic, growth factors, and adaptive cytokines significantly correlated with higher titers of IgM, IgA and IgG subclasses (p < 0.05). The strong and significant positive correlations between mucosal antibodies and markers of GI suggest that GI may impact mucosal antibody profiles. These findings require further investigation to establish a plausible biological link between the local inflammatory milieu and its consequence on these genital antibodies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
33. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response.
- Author
-
Abdool Karim, Salim S., Churchyard, Gavin J., Abdool Karim, Quarraisha, and Lawn, Stephen D.
- Subjects
- *
HIV , *TUBERCULOSIS , *EPIDEMICS , *PREVENTIVE medicine , *EPIDEMIOLOGY - Abstract
The article provides information on HIV and tuberculosis epidemics in South Africa and how the government has responded to them. The first cases of AIDS in South Africa occurred in 1982 and the HIV epidemic has evolved through the concentrated epidemic phase, initiation of the generalised epidemic, rapid spread of HIV, and AIDS mortality phase. Tuberculosis was introduced in the 17th century into South Africa by the arrival of European immigrants from Great Britain and the Netherlands. Achievements and innovations in the responses to HIV and tuberculosis are discussed. Steps for HIV and tuberculosis control are outlined.
- Published
- 2009
- Full Text
- View/download PDF
34. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.
- Author
-
Simon, Viviana, Ho, David D, and Abdool Karim, Quarraisha
- Subjects
- *
HIV , *AIDS research , *EPIDEMIOLOGY , *PATHOLOGY , *DISEASE management , *VIRUS research , *INTERNATIONAL cooperation on public health , *THERAPEUTICS research - Abstract
Summary The HIV-1 pandemic is a complex mix of diverse epidemics within and between countries and regions of the world, and is undoubtedly the defining public-health crisis of our time. Research has deepened our understanding of how the virus replicates, manipulates, and hides in an infected person. Although our understanding of pathogenesis and transmission dynamics has become more nuanced and prevention options have expanded, a cure or protective vaccine remains elusive. Antiretroviral treatment has transformed AIDS from an inevitably fatal condition to a chronic, manageable disease in some settings. This transformation has yet to be realised in those parts of the world that continue to bear a disproportionate burden of new HIV-1 infections and are most affected by increasing morbidity and mortality. This Seminar provides an update on epidemiology, pathogenesis, treatment, and prevention interventions pertinent to HIV-1. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
35. COVID-19 and global equity for health: The good, the bad, and the wicked.
- Author
-
Geng, Elvin H., Reid, Michael J. A., Goosby, Eric, and Abdool-Karim, Quarraisha
- Subjects
- *
COVID-19 pandemic , *HEALTH equity , *WORLD health , *COVID-19 vaccines , *AUTHORSHIP collaboration - Abstract
Elvin Geng and co-authors discuss monitoring and achieving equity in provision of vaccines for COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
36. Transient association between semen exposure and biomarkers of genital inflammation in South African women at risk of HIV infection.
- Author
-
Jewanraj, Janine, Ngcapu, Sinaye, Osman, Farzana, Ramsuran, Veron, Fish, Maryam, Mtshali, Andile, Singh, Ravesh, Mansoor, Leila E, Abdool Karim, Salim S, Abdool Karim, Quarraisha, Passmore, Jo‐Ann S, and Liebenberg, Lenine J P
- Subjects
- *
HIV infections , *SOUTH Africans , *SEMEN , *GENITALIA , *SEXUAL intercourse - Abstract
Introduction: Semen induces mucosal changes in the female reproductive tract to improve pregnancy outcomes. Since semen‐induced alterations are likely short‐lived and genital inflammation is linked to HIV acquisition in women, we investigated the contribution of recent semen exposure on biomarkers of genital inflammation in women at high HIV risk and the persistence of these associations. Methods: We assessed stored genital specimens from 152 HIV‐negative KwaZulu‐Natal women who participated in the CAPRISA 008 trial between November 2012 and October 2014. During the two‐year study period, 651 vaginal specimens were collected biannually (mean five samples per woman). Cervicovaginal lavage (CVL) was screened for prostate‐specific antigen (PSA) by ELISA, whereas Y‐chromosome DNA (YcDNA) detection and quantification were conducted by RT‐PCR, representing semen exposure within 48 hours (PSA+YcDNA+) and semen exposure within three to fifteen days (PSA−YcDNA+). Soluble protein concentrations were measured in CVLs by multiplexed ELISA. T‐cell frequencies were assessed in cytobrushes by flow‐cytometry, and vulvovaginal swabs were used to detect common vaginal microbes by PCR. Linear mixed models adjusting for factors associated with genital inflammation and HIV risk were used to assess the impact of semen exposure on biomarkers of inflammation over multiple visits. Results: Here, 19% (125/651) of CVLs were PSA+YcDNA+, 14% (93/651) were PSA−YcDNA+ and 67% (433/651) were PSA−YcDNA−. Semen exposure was associated with how often women saw their partners, the frequency of vaginal sex in the past month, HSV‐2 antibody detection, current gonorrhoea infection and Nugent Score. Both PSA detection (PSA+YcDNA+) and higher cervicovaginal YcDNA concentrations predicted increases in several cytokines, barrier‐related proteins (MMP‐2, TIMP‐1 and TIMP‐4) and activated CD4+CCR5+HLA‐DR+ T cells (β = 0.050; CI 0.001 to 0.098; p = 0.046) and CD4+HLA‐DR+ T cells (β = 0.177; CI 0.016 to 0.339; p = 0.032) respectively. PSA detection was specifically associated with raised pro‐inflammatory cytokines (including IL‐6, TNF‐α, IP‐10 and RANTES), and with the detection of BVAB2 (OR = 1.755; CI 1.116 to 2.760; p = 0.015), P. bivia (OR = 1.886; CI 1.102 to 3.228; p = 0.021) and Gardnerella vaginalis (OR = 1.815; CI 1.093 to 3.015; p = 0.021). Conclusions: More recent semen exposure was associated with raised levels of inflammatory biomarkers and the detection of BV‐associated microbes, which declined by three to fifteen days of post‐exposure. Although transient, semen‐induced alterations may have implications for HIV susceptibility in women. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
37. Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review.
- Author
-
Mahomed, Sharana, Garrett, Nigel, Baxter, Cheryl, Karim, Quarraisha Abdool, Karim, Salim S Abdool, Abdool Karim, Quarraisha, and Abdool Karim, Salim S
- Subjects
- *
HIV antibodies , *MONOCLONAL antibodies , *CLINICAL trials , *HIV , *HIV infections , *HIV prevention , *THERAPEUTIC use of monoclonal antibodies , *IMMUNOGLOBULINS , *IMMUNIZATION , *SYSTEMATIC reviews , *VIRAL antibodies - Abstract
Passive immunization with broadly neutralizing antibodies (bnAbs) is a promising approach to reduce the 1.7 million annual human immunodeficiency virus (HIV) infections globally. Early studies on bnAbs showed safety in humans, but short elimination half-lives and low potency and breadth. Since 2010, several new highly potent bnAbs have been assessed in clinical trials alone or in combination for HIV prevention. Published data indicate that these bnAbs are safe and have a half-life ranging from 15 to 71 days. Only intravenous VRC01 has advanced to an efficacy trial, with results expected in late 2020. If bnAbs are shown to be effective in preventing HIV infection, they could fast-track vaccine development as correlates of protection, and contribute as passive immunization to achieving the goal of epidemic control. The purpose of the current review is to describe the current status and provide a synopsis of the available data on bnAbs in clinical trials for HIV prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
38. Importance of early identification of PrEP breakthrough infections in a generalized HIV epidemic: a case report from a PrEP demonstration project in South Africa.
- Author
-
Naicker, Cherise L., Mansoor, Leila E., Dawood, Halima, Naidoo, Kogieleum, Singo, Denzhe, Matten, David, Williamson, Carolyn, and Abdool Karim, Quarraisha
- Subjects
- *
HIV infections , *IMMUNE reconstitution inflammatory syndrome , *VIRAL load , *PILOT projects , *HIV antibodies , *HIV prevention , *BREAKTHROUGH infections , *PREVENTION of epidemics , *ANTI-HIV agents , *COMBINATION drug therapy , *ORAL drug administration , *HETEROCYCLIC compounds , *HIV seroconversion , *RETROSPECTIVE studies , *PREVENTIVE health services , *LAMIVUDINE , *TREATMENT effectiveness , *RESEARCH funding , *DRUG resistance in microorganisms , *AZIDOTHYMIDINE , *HIV - Abstract
Background: The World Health Organisation recommends the use of tenofovir-containing pre-exposure prophylaxis (PrEP) as an additional Human Immunodeficiency Virus (HIV) prevention choice for men and women at substantial risk of HIV infection. PrEP could fill an important HIV prevention gap, especially for sexually active young women who are limited in their ability to negotiate mutual monogamy or condom use. As PrEP is scaled up in high HIV incidence settings, it is crucial to consider the importance of early identification of HIV infection during PrEP use, to allow for rapid discontinuation of PrEP to reduce the risk of antiretroviral (ARV) resistance. The purpose of this case study is to provide this critical evidence.Case Presentation: This report describes a 20-year-old woman in a HIV sero-discordant relationship who initiated oral PrEP (tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC)) through a demonstration project (CAPRISA 084) in October 2017. Despite good adherence throughout her PrEP use, she tested HIV antibody positive at month nine of study participation. Retrospective testing showed increasing HIV viral load over time, and retrospective use of fourth-generation rapid HIV tests showed HIV detection (positive antigen/antibody) at month one. Sequencing confirmed a dominant wild type at month one with dual therapy resistance patterns emerging by month three (M184V and K65R mutations), which is suggestive of protracted PrEP use during an undetected HIV infection. The participant was referred to infectious diseases for further management of her HIV infection and was initiated on a first line, tenofovir-sparing regimen. At the time of this report (January 2020), the participant had been on ARV- therapy (ART) for 13 months and had no signs of either clinical, immunologic or virologic failure.Conclusions: This case report highlights the importance of appropriate HIV screening during wider oral PrEP scale-up in high HIV incidence settings to circumvent the consequences of prolonged dual therapy in an undiagnosed HIV infection and in turn prevent ARV resistance. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
39. Plasma concentration of injectable contraceptive correlates with reduced cervicovaginal growth factor expression in South African women.
- Author
-
Molatlhegi, Refilwe P., Liebenberg, Lenine J., Leslie, Alasdair, Noel-Romas, Laura, Mabhula, Amanda, Mchunu, Nobuhle, Perner, Michelle, Birse, Kenzie, Ngcapu, Sinaye, Adamson, John H., Govender, Katya, Garrett, Nigel J., Samsunder, Natasha, Burgener, Adam D., Abdool Karim, Salim S., Abdool Karim, Quarraisha, Passmore, Jo-Ann S., and McKinnon, Lyle R.
- Published
- 2020
- Full Text
- View/download PDF
40. Integrated provision of topical pre‐exposure prophylaxis in routine family planning services in South Africa: a non‐inferiority randomized controlled trial.
- Author
-
Mansoor, Leila E, Yende‐Zuma, Nonhlanhla, Baxter, Cheryl, Mngadi, Kathryn T, Dawood, Halima, Gengiah, Tanuja N, Samsunder, Natasha, Schwartz, Jill L, Doncel, Gustavo F, and Abdool Karim, Quarraisha
- Subjects
- *
PRE-exposure prophylaxis , *FAMILY planning services , *RANDOMIZED controlled trials , *HIV prevention - Abstract
Introduction: Tenofovir‐containing oral pre‐exposure prophylaxis (PrEP) is recommended for those at substantial risk as part of combination HIV prevention. However, there are limited data, beyond clinical trial settings, to guide the introduction of PrEP in healthcare services with adequate levels of adherence. Since young women in Africa are at high risk of HIV and likely to utilize family planning (FP) services, the feasibility, acceptability and effectiveness of integrating topical PrEP provision into routine FP services was assessed. Methods: This two‐arm, randomized controlled, non‐inferiority, open‐label extension trial was undertaken in urban and rural KwaZulu‐Natal, South Africa. HIV‐negative eligible women (n = 372) from the parent trial (Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004) were randomized to receive tenofovir gel either through intervention (FP clinics, n = 189) or control clinics (CAPRISA research clinics, n = 183). Non‐inferiority was predefined as gel use in the intervention clinics would be no more than 20% lower than in the control clinics. Adherence, retention and HIV incidence rates were assessed. Results: Women were enrolled between November 2012 and October 2014, and followed up for 682.3 women‐years (mean = 22 months). Baseline characteristics of women in intervention and control clinics were comparable and retention rates were 92.1% and 92.3% respectively. Women in intervention clinics and control clinics returned on average 5.2 (95% confidence interval (CI): 4.7 to 5.7) and 5.7 (CI: 5.2 to 6.2) used gel applicators per month respectively, with a mean difference of −0.47 (CI: −1.16 to 0.21). Per‐protocol estimates were on average 5.5 (CI: 5.0 to 6.1) and 5.8 (CI: 5.3 to 6.3) respectively, with a mean difference of −0.25 (CI: −0.98 to 0.48), meeting the non‐inferiority criteria. Adherence, based on proportion of reported sex acts covered by two gel doses, was 79.9% (CI: 76.7 to 83.2) in intervention compared with 73.9% (CI: 70.7 to 77.1) in control clinics; mean difference:6.0% (CI: 1.5 to 10.6) (p = 0.009). HIV incidence rates were 3.5 (CI: 1.8 to 6.0) and 3.6 (CI: 1.9 to 6.3) per 100 women‐years in intervention and control clinics respectively. Both these incidence rates were lower than the age‐standardized rate of 6.2 per 100 women‐years (n = 444) in the placebo arm of the parent trial (p = 0.019). Conclusions: Provision of topical PrEP as part of an integrated FP service achieved higher adherence, and was as feasible, acceptable and effective in preventing HIV as provision through a research setting. This provides useful evidence for scale‐up of oral PrEP in urban and rural high burden communities. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
41. Performance of rapid antigen tests in identifying Omicron BA.4 and BA.5 infections in South Africa.
- Author
-
Samsunder, Natasha, Lustig, Gila, de Vos, Margaretha, Ngcapu, Sinaye, Giandhari, Jennifer, Tshiabuila, Derek, San, Emmanuel James, Lewis, Lara, Kharsany, Ayesha BM, Cawood, Cherie, de Oliveira, Tulio, Abdool Karim, Quarraisha, Abdool Karim, Salim, Escadafal, Camille, Naidoo, Kogieleum, and Sivro, Aida
- Subjects
- *
ANTIGEN analysis , *COVID-19 testing , *SARS-CoV-2 Omicron variant , *SARS-CoV-2 , *COVID-19 - Abstract
• Evolution of SARS-CoV-2 continues to challenge the existing COVID-19 prevention measures. • Performance of the SARS-CoV-2 Antigen Rapid test from Hangzhou Alltest Biotech (nasal swab) and the Standard Q COVID-19 rapid antigen test from SD biosensor (nasopharyngeal swab) was compared to the Abbott Realtime SARS-CoV-2 assay on samples collected from 540 study participants during the BA.4 and BA.5 SARS-CoV-2 wave in South Africa. • Performance of SARS-CoV-2 rapid antigen tests was not adversely affected by the presence of additional mutations in the BA.4 and BA.5 Omicron subvariants. Concerns around accuracy and performance of rapid antigen tests continue to be raised with the emergence of new SARS-CoV-2 variants. To evaluate the performance of two widely used SARS-CoV-2 rapid antigen tests during BA.4/BA.5 SARS-CoV-2 wave in South Africa (May – June 2022). A prospective field evaluation compared the SARS-CoV-2 Antigen Rapid test from Hangzhou AllTest Biotech (nasal swab) and the Standard Q COVID-19 Rapid Antigen test from SD Biosensor (nasopharyngeal swab) to the Abbott RealTime SARS-CoV-2 assay (nasopharyngeal swab) on samples collected from 540 study participants. Overall 28.52% (154/540) were SARS-CoV-2 RT-PCR positive with median cycle number value of 12.30 (IQR 9.30–19.40). Out of the 99 successfully sequenced SARS-CoV-2 positive samples, 18 were classified as BA.4 and 56 were classified as BA.5. The overall sensitivities of the AllTest SARS-CoV-2 Ag test and Standard Q COVID-19 Ag test were 73.38% (95% CI 65.89–79.73) and 74.03% (95% CI 66.58–80.31) and their specificities were 97.41% (95% CI 95.30–98.59) and 99.22% (95% CI 97.74–99.74) respectively. Sensitivity was >90% when the cycle number value was <20. The sensitivity of both rapid tests was >90% in samples infected with Omicron sub-lineage BA.4 and BA.5. Accuracy of tested rapid antigen tests that target the nucleocapsid SARS-CoV-2 protein, were not adversely affected by BA.4 and BA.5 Omicron sub-variants. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
42. Repeat HIV testing practices in the era of HIV self-testing among adults in KwaZulu-Natal, South Africa.
- Author
-
Harichund, Charlene, Kunene, Pinky, Simelane, Sinenhlanhla, Abdool Karim, Quarraisha, and Moshabela, Mosa
- Subjects
- *
DIAGNOSIS of HIV infections , *HIV prevention , *HIV status , *MEDICAL education , *PUBLIC health - Abstract
Repeat HIV testing is important in high HIV burden communities to enable sustainability of prevention initiatives; however, an understanding of repeat testing practices is limited. Additional HIV testing approaches may be required to increase testing. HIV self-testing is an additional testing approach, but knowledge on its potential for repeat testing is limited. This study explored repeat HIV testing practices and uptake of HIV self-testing among repeat testers, following exposure to HIV self-testing. HIV testing practices were explored at two time points. During Phase 1, eighty in-depth interviews were conducted among 40 consenting adults, and 30 telephonic contacts were completed during Phase 2. Framework analysis was used to analyse the transcripts from the in-depth interviews. The practice of repeat HIV testing is primarily influenced by HIV status awareness and risk exposure. Thirteen regular testers and one HIV naïve tester at baseline had undergone repeat testing through the use of a traditional testing approach such as HIV counselling and testing as reported in Phase 2. HIV self-testing has a role among repeat testers, but affordability and access are barriers. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
43. Acceptability of HIV self-testing among men and women in KwaZulu-Natal, South Africa.
- Author
-
Harichund, Charlene, Moshabela, Mosa, Kunene, Pinky, and Abdool Karim, Quarraisha
- Subjects
- *
DIAGNOSIS of HIV infections , *AUTONOMY (Psychology) , *COUNSELING , *DISCUSSION , *FOCUS groups , *INTERVIEWING , *MEN'S health , *MOTIVATION (Psychology) , *SELF-efficacy , *SEX distribution , *WOMEN'S health , *SYSTEMATIC reviews , *QUALITATIVE research , *JUDGMENT sampling , *LITERATURE reviews , *HIV seroconversion , *PATIENTS' attitudes , *SELF diagnosis , *AIDS serodiagnosis - Abstract
Successful implementation of Universal Test and Treat as a strategy to achieve the 90-90-90 target requires higher HIV testing rates. Currently, uptake of HIV testing is not optimal which has directed research initiatives towards identification of additional HIV testing methods. HIV self-testing (HIVST) has received growing attention as a complementary testing approach as it overcomes barriers that are commonly associated with current HIV testing methods. In sub-Saharan Africa, acceptability rates showed a gendered pattern of men benefitting more than women, with limited evidence to explain this difference. This study assessed whether men or women in KwaZulu-Natal displayed a higher acceptance of HIVST and also explored factors that influenced and motivated their acceptability. Participants were recruited through purposive sampling at two clinical research sites to participate and underwent qualitative assessments. The outcomes from focus group discussions coupled with findings from a scoping review informed the design and data collection instruments for in-depth interviews. A randomised cross-over study design exposed participants to HIV counselling and testing and HIVST, accompanied by before (baseline) and after in-depth interviews. HIVST was acceptable among most participants with acceptability higher in women. Men preferred HIVST due to convenience and efficiency, whilst women favoured HIVST due to its potential to provide autonomy and empowerment. Also, lack of HIV counselling and managing a positive HIV result as well as linkage to care were raised as deterrents of HIVST. As HIVST was acceptable by most participants, future research efforts should be directed towards evaluating the feasibility of its introduction into the public health sector. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
44. 'You'll always stay right': understanding vaginal products and the motivations for use among adolescent and young women in rural KZN.
- Author
-
Humphries, Hilton, Mehou-Loko, Celia, Phakathi, Sithembile, Mdladla, Makhosazana, Fynn, Lauren, Knight, Lucia, and Abdool Karim, Quarraisha
- Subjects
- *
YOUNG women , *MANUFACTURED products , *RURAL women - Abstract
The use of vaginal products may increase the risk of HIV infection by affecting the vaginal biome. Understanding what vaginal products young women are using, and why, is key to assessing the complexity of sexual health and risk. This study reports on findings from research with adolescent and young women in rural KwaZulu-Natal about the vaginal products they use and motivations for using them. The study identified over 26 products that young women used to enhance their sexual experience and found some young women spent time preparing and sourcing vaginal products in order to pleasure and retain partners. Opinions differed about vaginal product use. While some women perceived that vaginal products could provide a means of out-performing other women, retaining a partner and providing sexual autonomy, there was a stigma attached to using them. Study findings highlight the social value of using vaginal products, especially in settings where partner retention is linked to economic survival. Expanding our understanding of what products are used and the reasons young women use them warrants continued investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
45. Residual T cell activation and skewed CD8+ T cell memory differentiation despite antiretroviral therapy-induced HIV suppression.
- Author
-
Tanko, Ramla F., Soares, Andreia P., Masson, Lindi, Garrett, Nigel J., Samsunder, Natasha, Abdool Karim, Quarraisha, Abdool Karim, Salim S., Riou, Catherine, and Burgers, Wendy A.
- Subjects
- *
HIV infections , *T cell differentiation , *HIGHLY active antiretroviral therapy , *T cells , *MICROBIAL virulence , *DISEASES - Abstract
HIV infection results in excessive T cell activation and dysfunction which may persist even during effective antiretroviral therapy (ART). The dynamics of immune ‘deactivation’ and extent to which T cell memory subsets normalize after ART are unclear. We longitudinally assessed the influence of 1 year of ART on the phenotype of T cells in HIV-infected African women, relative to matched HIV-uninfected women, using activation (CD38, HLA-DR) and differentiation markers (CD27, CD45RO). ART induced a substantial reduction in T cell activation, but remained higher than HIV-uninfected controls. ART largely normalized the distribution of CD4+ T cell memory subsets, while the distribution of CD8+ T cell memory subsets remained significantly skewed compared to HIV-uninfected individuals. Thus, there was a considerable but only partial reversal of T cell defects upon ART. Understanding T cell impairment may provide important insights into mechanisms of HIV pathogenesis in the era of ART. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
46. Ex vivo HIV entry into blood CD4+ T cells does not predict heterosexual HIV acquisition in women.
- Author
-
Joag, Vineet, Sivro, Aida, Yende-Zuma, Nonhlanhla, Imam, Hajra, Samsunder, Natasha, Abdool Karim, Quarraisha, Abdool Karim, Salim, McKinnon, Lyle, and Kaul, Rupert
- Subjects
- *
HIV infections -- Immunological aspects , *CD4 antigen , *T cells , *HETEROSEXUALITY , *DISEASES in women , *DISEASE susceptibility , *PHYSIOLOGY - Abstract
Background: A blood-based assay that could quantify HIV susceptibility would be very valuable for HIV prevention research. Previously, we developed and validated an ex vivo, flow-based, HIV entry assay to assess genital HIV susceptibility in endocervical CD4+ T cells. Methods: Here we assessed whether this tool could be used to predict HIV risk using blood-derived CD4+ T cells in a rigorously-blinded, nested case-control study using blood samples collected from high-risk, HIV-uninfected South African women enrolled in the CAPRISA 004 clinical trial. Cases, subsequently acquiring HIV were sampled prior to HIV infection and compared with controls, who remained HIV-uninfected. The primary endpoint was ex vivo entry of a CCR5-tropic HIV founder virus into blood CD4+ T cells. Secondary endpoints included HIV entry into CD4+ central (TCM) and effector (TEM) memory T cells, and into CD4+ T cell subsets expressing CCR5, CD69, CCR6, α4β1 or α4β7. Results: Compared to bulk CD4+ T cells (4.9% virus entry), CD4+ T cells expressing CCR5, CCR6 or α4β1 and TEM were highly susceptible (15.5%, 8.8%, 8.2% and 10.8% entry, respectively, all p<0.0001), while TCM, CD69+ or α4β7+ CD4+ cells were moderately susceptible (6.4%, 6.0% and 5.8% respectively, p ≤ 0.003). While the proportion of the aforementioned highly susceptible cells correlated with overall virus entry into CD4+ T cells within an individual (r = 0.68, 0.47, 0.67, and 0.60 respectively, p<0.0001), blood virus entry did not predict subsequent mucosal HIV acquisition after controlling for sexual behaviour and condom use (OR 0.92, 95% CI 0.77–1.11, p = 0.40). Conclusions: Although virus entry identified several previously known highly susceptible cellular HIV targets, blood HIV entry did not predict subsequent heterosexual HIV acquisition. Assessment of mucosal HIV susceptibility may require sampling at the site of HIV exposure. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
47. Exploratory analysis of the ecological variables associated with sexual health profiles in high-risk, sexually-active female learners in rural KwaZulu-Natal.
- Author
-
Humphries, Hilton, Osman, Farzana, Knight, Lucia, and Abdool Karim, Quarraisha
- Subjects
- *
SEXUAL health , *WOMEN'S sexual behavior , *PATHOGENIC microorganisms , *EXPLORATORY factor analysis - Abstract
Purpose: Young women are at high risk for negative sexual health outcomes. Despite their high risk, many sexually-active women never experience negative sexual health outcomes. This study explored the ecological risk factors associated with the risk profiles of sexually-active female high school-learners in rural KwaZulu-Natal, South Africa. Methods: Using baseline data from N = 596 sexually-active school-going women, we explored the ecological factors associated with being sexually-active and managing risk successfully [SARS] or unsuccessfully [SARU]. Generalised estimated equations (GEE) were applied to data collected at multiple levels while adjusting for school and other included variables. GEE were used to calculate probability of being SARU. Results: Amongst SARU learners, 21.9% had HIV, 38.6% had HSV-2, 12.5% were pregnant, 28.7% self-reported STI symptoms and 51.9% reported a previous pregnancy. Individual-level factors had the greatest impact on being SARU. Univariate and multivariate analysis highlighted several important partner factors associated with SARU. Age was significantly associated with the risk profiles (p<0.0001), a greater proportion of SARU learners were 18 or older compared to the SARS learners. The odds of being SARU decreased when ≥18 years (aOR = 0.2577, 95% CI 0.1462–0.4542) or if not falling pregnant was important (aOR = 0.6343, 95% CI 0.4218–0.9538). Having >1 HIV test (aOR = 2.2161, 95% CI 1.3964–3.5169) increased the odds a SARU profile. Conclusion: Individual and partner level factors are important for the sexual health profile of an adolescent female. While the exploratory findings require further research; managing multiple sexual health outcomes, tailoring responses around a risk profile and including partners is essential for successful interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
48. Identification and validation of a multi-assay algorithm for cross-sectional HIV incidence estimation in populations with subtype C infection.
- Author
-
Laeyendecker, Oliver, Konikoff, Jacob, Morrison, Douglas E, Brookmeyer, Ronald, Wang, Jing, Celum, Connie, Morrison, Charles S, Abdool Karim, Quarraisha, Pettifor, Audrey E, and Eshleman, Susan H
- Abstract
Introduction: Cross-sectional methods can be used to estimate HIV incidence for surveillance and prevention studies. We evaluated assays and multi-assay algorithms (MAAs) for incidence estimation in subtype C settings. Methods: We analysed samples from individuals with subtype C infection with known duration of infection (2442 samples from 278 adults; 0.1 to 9.9 years after seroconversion). MAAs included 1-4 of the following assays: Limiting Antigen Avidity assay (LAg-Avidity), BioRad-Avidity assay, CD4 cell count and viral load (VL). We evaluated 23,400 MAAs with different assays and assay cutoffs. We identified the MAA with the largest mean window period, where the upper 95% confidence interval (CI) of the shadow was <1 year. This MAA was compared to the LAg-Avidity and BioRad-Avidity assays alone, a widely used LAg algorithm (LAg-Avidity <1.5 OD-n + VL >1000 copies/mL), and two MAAs previously optimized for subtype B settings. We compared these cross-sectional incidence estimates to observed incidence in an independent longitudinal cohort. Results: The optimal MAA was LAg-Avidity <2.8 OD-n + BioRad-Avidity <95% + VL >400 copies/mL. This MAA had a mean window period of 248 days (95% CI: 218, 284), a shadow of 306 days (95% CI: 255, 359), and provided the most accurate and precise incidence estimate for the independent cohort. The widely used LAg algorithm had a shorter mean window period (142 days, 95% CI: 118, 167), a longer shadow (410 days, 95% CI; 318, 491), and a less accurate and precise incidence estimate for the independent cohort. Conclusions: An optimal MAA was identified for cross-sectional HIV incidence in subtype C settings. The performance of this MAA is superior to a testing algorithm currently used for global HIV surveillance. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
49. Secrecy, empowerment and protection: positioning PrEP in KwaZulu-Natal, South Africa.
- Author
-
Govender, Eliza, Mansoor, Leila, MacQueen, Kate, and Abdool Karim, Quarraisha
- Subjects
- *
PRE-exposure prophylaxis , *HIV prevention , *EMTRICITABINE-tenofovir , *SOCIOCULTURAL factors , *THERAPEUTICS , *ANTI-HIV agents , *INTERVIEWING , *RESEARCH methodology , *MEDICAL ethics , *POWER (Social sciences) , *PREVENTIVE health services , *PRIVACY , *RESEARCH funding , *SAFE sex - Abstract
The release of World Health Organisation guidelines recommending the prophylactic use of daily Truvada® for all populations at high risk of acquiring HIV opens the way for implementation of oral pre-exposure prophylaxis (PrEP). The impact of new prevention technologies is, however, dependent on demand creation strategies such as user awareness, acceptability and access, which in turn are influenced by sociocultural and gender norms. This study was conducted in three locations in KwaZulu-Natal, urban, rural and peri-urban, with six participatory workshops. Knowledge, desirable features of a product and demand positioning for PrEP were assessed using a participatory action media research process which included art-based activities and group discussion using a semi-structured interview schedule. The data were analysed using thematic analysis. The key themes that emerged in relation to product adoption were: ability to maintain secrecy of product use; the need for agency with personal choices around HIV prevention; and an increased desire for HIV protection. Findings reaffirm the influence of user engagement in understanding the sociocultural dynamics that influence demand creation for PrEP adoption. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
50. High mortality rates in men initiated on anti-retroviral treatment in KwaZulu-Natal, South Africa.
- Author
-
Naidoo, Kogieleum, Hassan-Moosa, Razia, Yende-Zuma, Nonhlanhla, Govender, Dhineshree, Padayatchi, Nesri, Dawood, Halima, Adams, Rochelle Nicola, Govender, Aveshen, Chinappa, Tilagavathy, Abdool-Karim, Salim, and Abdool-Karim, Quarraisha
- Subjects
- *
ANTIRETROVIRAL agents , *AIDS treatment , *MORTALITY of AIDS patients , *AIDS patients , *PUBLIC health - Abstract
In attaining UNAIDS targets of 90-90-90 to achieve epidemic control, understanding who the current utilizers of HIV treatment services are will inform efforts aimed at reaching those not being reached. A retrospective chart review of CAPRISA AIDS Treatment Program (CAT) patients between 2004 and 2013 was undertaken. Of the 4043 HIV-infected patients initiated on ART, 2586 (64.0%) were women. At ART initiation, men, compared to women, had significantly lower median CD4+ cell counts (113 vs 131 cells/mm3, p <0.001), lower median body mass index (BMI) (21.0 vs 24.2 kg/m2, p<0.001), higher mean log viral load (5.0 vs 4.9 copies/ml, p<0.001) and were significantly older (median age: 35 vs. 32 years, p<0.001). Men had higher mortality rates compared to women, 6.7 per 100 person-years (p-y), (95% CI: 5.8–7.8) vs. 4.4 per 100 p-y, (95% CI: 3.8–5.0); mortality rate ratio: 1.54, (95% CI: 1.27–1.87), p <0.001. Age-standardised mortality rate was 7.9 per 100 p-y (95% CI: 4.1–11.7) for men and 5.7 per 100 p-y (95% CI: 2.7 to 8.6) for women (standardised mortality ratio: 1.38 (1.15 to 1.70)). Mean CD4+ cell count increases post-ART initiation were lower in men at all follow-up time points. Men presented later in the course of their HIV disease for ART initiation with more advanced disease and experienced a higher mortality rate compared to women. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.